Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9586)
All Articles published online
|
Publishing Process of This Article
|
May 28, 2021 (publication date) through Mar 25, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Chen SL, Wang GP, Shi DR, Yao SH, Chen KD, Yao HP. RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets. World J Gastroenterol 2021; 27(20): 2507-2520 [PMID: 34092972 DOI: 10.3748/wjg.v27.i20.2507] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Chen SL, Wang GP, Shi DR, Yao SH, Chen KD, Yao HP. RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets. World J Gastroenterol 2021; 27(20): 2507-2520 [PMID: 34092972 DOI: 10.3748/wjg.v27.i20.2507] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i20/2507.htm |
| Number | Citing Articles |
| 1 |
Tushar Deb Nath, Attrayo Mukherjee, Subhash C. Chauhan, Debasish Bandyopadhyay. Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. International Journal of Molecular Sciences 2026; 27(6): 2707 doi: 10.3390/ijms27062707
|
| 2 |
Jia-Le Zhang, Lin-Wei Zhu, Jia Ji, Tao-Ming Tang, Miao-Jin Zhu, Hang-Ping Yao. Antibody-drug conjugates specifically regulate tumor microenvironment: A promising strategy for pancreatic cancer treatment. Hepatobiliary & Pancreatic Diseases International 2025; doi: 10.1016/j.hbpd.2025.12.010
|
| 3 |
Kai Wu, Jia Ji, Jingying Pan, Miaojin Zhu, Jiale Zhang, Ting Sun, Dan Lv, Mudan Wei, Minghai Wang, Hangping Yao. MSP-RON signaling in liver pathobiology and as an emerging therapeutic target: a review of the current evidence. Cell Communication and Signaling 2025; 23(1) doi: 10.1186/s12964-025-02407-5
|
| 4 |
James C. Davis, Susan E. Waltz. The MET Family of Receptor Tyrosine Kinases Promotes a Shift to Pro-Tumor Metabolism. Genes 2024; 15(7): 953 doi: 10.3390/genes15070953
|
| 5 |
Baohui Qi, Fei Wang, Huan He, Mengmeng Fan, Liping Hu, Li Xiong, Guowei Gong, Shengmin Shi, Xiaomeng Song. Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent. European Journal of Medicinal Chemistry 2022; 239: 114561 doi: 10.1016/j.ejmech.2022.114561
|
| 6 |
Yuemiao Xu, Jiahan Le, Jiangjiang Qin, Yuhua Zhang, Jiaying Yang, Zhuo Chen, Changyu Li, Xiang Qian, Aiqin Zhang. Decoding the microbiota metabolome in hepatobiliary and pancreatic cancers: Pathways to precision diagnostics and targeted therapeutics. Pharmacological Research 2024; 208: 107364 doi: 10.1016/j.phrs.2024.107364
|